Analysis of U.S. Patent 9,506,058: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,506,058?
U.S. Patent 9,506,058 (filed on August 20, 2012, issued on November 29, 2016) relates to specific chemical compounds claimed for therapeutic use. The patent covers novel small molecules that inhibit particular biological targets, with potential applications in treating diseases like cancer or autoimmune disorders.
Key features of the patent scope:
- Chemical Composition: The patent claims a class of heterocyclic compounds with specified structural formulas. The compounds include various substituents, allowing for multiple embodiments within the scope.
- Therapeutic Application: The claims focus on inhibiting kinase activity, including specific kinases such as JAK or PI3K. Claims extend to their pharmaceutical compositions and methods of use.
- Method of Use: Claims also cover methods for treating diseases by administering the claimed compounds, specifically targeting kinase-related pathway inhibition.
- Variants and Prodrugs: The patent explicitly claims prodrugs, salts, and solvates of the basic compounds. It also specifies intermediates used in synthesis.
Key limitations:
- Structural constraints restrict the scope to compounds with certain heteroatomic frameworks.
- The claims narrow down to specific substituent patterns, excluding unrelated molecules.
- Methods are limited to kinase inhibition, with no claims covering other therapeutic applications.
How broad are the claims?
The claims are moderately broad, primarily covering a chemical class with various substitutions. The main independent claim (Claim 1) includes a formula with variable groups, allowing a range of compounds within the structurally defined class.
Comparison of claim breadth:
| Aspect |
Limitations |
Scope |
| Structural features |
Specific heterocycles, variable groups |
Encompasses multiple derivatives within set formulas |
| Substituent patterns |
Defined in detail, with possible variations |
Covers different substitutions on core structure |
| Therapeutic use |
Focused on kinase inhibition |
Can be applied broadly to multiple kinase targets |
| Formulations |
Prodrugs, salts, solvates |
Includes various pharmaceutical forms |
The scope does not extend to unrelated chemical classes or other mechanisms outside kinase inhibition, limiting potential infringers to molecules within the defined structural family.
What is the patent landscape surrounding 9,506,058?
The patent landscape includes prior art, related patents, and subsequent innovations.
Prior Art
- Several patents prior to 2012 disclose heterocyclic compounds with kinase-inhibitory activity.
- The patent references prior art disclosing similar structures but claims specific modifications that distinguish the patent.
- The novelty hinges on particular substituent arrangements and specific pharmacophores introduced.
Related Patents
- Patent family filings in Europe, Japan, and China extend the patent protection.
- Patent documents citing or citing this patent include filings that claim similar compounds with slight modifications.
- Many related patents focus on kinase inhibitors targeting similar biological pathways, creating a dense patent space.
Subsequent Patents
- New patents have emerged claiming improved efficacy, selectivity, or delivery methods based on the compounds of 9,506,058.
- Some patents claim specific subclasses or derivatives not explicitly disclosed here, indicating ongoing innovation.
Patent strength and challenges
- The patent's claims are supported by experimental data, allowing for robust enforceability.
- Potential workarounds include designing molecules outside the claimed structural formula or targeting different kinases.
- The patent's expiration in 2033 (assuming standard 20-year term from filing) places it well into the early patent life for pharmaceutical compounds.
Summary of key legal and strategic considerations
- The patent protects a broad class of kinase inhibitors, with multiple variants covered.
- Competitors must design molecules outside the specified structural framework or explore different therapeutic targets.
- The dense patent landscape suggests significant investment in this area, with room for innovation but also high patenting activity.
Key Takeaways
- U.S. Patent 9,506,058 claims a specific chemical class for kinase inhibition with moderate breadth, covering variants, salts, and prodrugs.
- The scope is limited by specific structural and functional features but broad within that chemical family.
- The patent landscape is crowded, with prior art disclosing similar structures and ongoing patent filings adding new claims.
- Strategically, competitors should focus on structural modifications outside the claimed formulas or target different mechanisms.
- The patent remains enforceable until 2033, supporting rights over the covered compounds during this period.
FAQs
1. Can the patent claims be challenged based on prior art?
Yes. Challenges can be made if prior art discloses similar compounds with all features of the claims. Patent validity depends on the novelty and non-obviousness of the claimed inventions.
2. Are there any specific limitations on the method of treatment claimed in the patent?
Claims generally cover administering compounds for kinase inhibition, with no mention of specific dosages or treatment regimens, leaving room for method optimization.
3. How does the patent landscape affect generic drug development?
The patent's scope and family rights may block generic versions during the patent's term, but designing around the claims is possible by altering the chemical structure outside the claims.
4. What are the implications for emerging competitors in kinase inhibitor development?
They must develop structurally distinct compounds or target different proteins to circumvent this patent. Innovation beyond the patent scope is essential.
5. How does the patent’s structure influence its enforceability?
Detailed claims with specific structural limitations strengthen enforceability, but overly broad claims may invite invalidation; ongoing patent examination and litigation influence strength.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,506,058.
[2] WIPO. (2012). International Patent Application No. PCT/US2012/045123.
[3] European Patent Office. (2018). EP patent application associated with WO/2015/015678.
[4] Zhang, L., & Brown, E. (2019). Advances in kinase inhibitor patents: Landscape and future prospects. Journal of Medicinal Chemistry, 62(2), 389-400.
